ketorolac has been researched along with Local Neoplasm Recurrence in 11 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses." | 5.38 | NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. ( Baum, M; Dekock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Pachmann, K; Retsky, M; Rogers, R; Vaidya, JS, 2012) |
| "Focusing on a high-risk group with preoperative inflammation could lead to a clinical trial to test the effect of ketorolac on cancer outcome." | 4.90 | Perspectives in anaesthesia for cancer surgery. ( De Kock, M; Forget, P, 2014) |
| " Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival." | 3.91 | Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. ( Bhasin, M; Bhasin, SS; Bielenberg, DR; Chang, J; Fishbein, A; Gartung, A; Gilligan, MM; Hammock, BD; Huang, S; Kieran, MW; Panigrahy, D; Piwowarski, J; Schmidt, BA; Serhan, CN; Soler-Ferran, D; Sparks, MA; Staffa, SJ; Sukhatme, V; Sukhatme, VP; Sulciner, ML; Yang, H; Yang, J, 2019) |
| "This retrospective analysis suggests that intraoperative administration of ketorolac decreases the risk of breast cancer relapse compared with other analgesícs." | 3.76 | Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. ( Berliere, M; De Kock, M; Forget, P; Legrand, C; Machiels, JP; Nussbaum, B; Vandenhende, J, 2010) |
| "This may also explain sudden confusion and dementia for the elderly after surgery." | 1.48 | Breast Cancer Relapse, Post-Surgical Confusion, and Dementia in the Elderly: An Unexpected Connection but with the Same Proposed Solution. ( Forget, P; Retsky, MW, 2018) |
| "Eighty patients with advanced ovarian cancer (International Federation of Gynecologists and Obstetricians, stage IIIC and IV) undergoing surgery between January 2000 and March 2011 were studied." | 1.39 | The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population. ( Assel, M; Brañes, J; Cartagena, J; Echevarría, GC; Lacassie, HJ, 2013) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| "Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses." | 1.38 | NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. ( Baum, M; Dekock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Pachmann, K; Retsky, M; Rogers, R; Vaidya, JS, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| de Castro Araujo, BL | 1 |
| de Oliveira, JL | 1 |
| Rezende, JFN | 1 |
| Noguera, WS | 1 |
| de Melo, AC | 1 |
| Thuler, LCS | 1 |
| Connolly, JG | 1 |
| Scarpa, JR | 1 |
| Gupta, HV | 1 |
| Tan, KS | 1 |
| Mastrogiacomo, B | 1 |
| Dycoco, J | 1 |
| Caso, R | 1 |
| Jones, GD | 1 |
| Sanchez-Vega, F | 1 |
| Adusumilli, PS | 1 |
| Rocco, G | 1 |
| Isbell, JM | 1 |
| Bott, MJ | 1 |
| Irie, T | 1 |
| McCormick, PJ | 1 |
| Fischer, GW | 1 |
| Jones, DR | 1 |
| Mincer, JS | 1 |
| Ben-Eliyahu, S | 1 |
| Golan, T | 1 |
| Desmedt, C | 1 |
| Demicheli, R | 2 |
| Fornili, M | 1 |
| Bachir, I | 1 |
| Duca, M | 1 |
| Viglietti, G | 1 |
| Berlière, M | 3 |
| Piccart, M | 1 |
| Sotiriou, C | 1 |
| Sosnowski, M | 1 |
| Forget, P | 6 |
| Biganzoli, E | 1 |
| Retsky, MW | 1 |
| Panigrahy, D | 1 |
| Gartung, A | 1 |
| Yang, J | 1 |
| Yang, H | 1 |
| Gilligan, MM | 1 |
| Sulciner, ML | 1 |
| Bhasin, SS | 1 |
| Bielenberg, DR | 1 |
| Chang, J | 1 |
| Schmidt, BA | 1 |
| Piwowarski, J | 1 |
| Fishbein, A | 1 |
| Soler-Ferran, D | 1 |
| Sparks, MA | 1 |
| Staffa, SJ | 1 |
| Sukhatme, V | 1 |
| Hammock, BD | 1 |
| Kieran, MW | 1 |
| Huang, S | 1 |
| Bhasin, M | 1 |
| Serhan, CN | 1 |
| Sukhatme, VP | 1 |
| Lacassie, HJ | 1 |
| Cartagena, J | 1 |
| Brañes, J | 1 |
| Assel, M | 1 |
| Echevarría, GC | 1 |
| Machiels, JP | 2 |
| Coulie, PG | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 2 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| De Kock, M | 3 |
| Vandenhende, J | 1 |
| Nussbaum, B | 1 |
| Retsky, M | 1 |
| Rogers, R | 1 |
| Hrushesky, WJ | 1 |
| Gukas, I | 1 |
| Vaidya, JS | 1 |
| Baum, M | 1 |
| Dekock, M | 1 |
| Pachmann, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.[NCT01806259] | Phase 3 | 203 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 93 |
| NaCl 0.9% 3mL | 105 |
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 80 |
| NaCl 0.9% 3mL | 96 |
1 review available for ketorolac and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Perspectives in anaesthesia for cancer surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Breast Neoplasms; Clinical Trials as Topic; Fem | 2014 |
10 other studies available for ketorolac and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Impact of Non-Steroidal Anti-Inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Female; Humans; Isoxazoles; Kaplan-Me | 2020 |
Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis.
Topics: Adenocarcinoma of Lung; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Gene Regulatory | 2021 |
Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes.
Topics: Body Mass Index; Breast Neoplasms; Humans; Ketorolac; Neoplasm Recurrence, Local; Perioperative Peri | 2018 |
Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Intraoperative Care; Ketorolac; Midd | 2018 |
Breast Cancer Relapse, Post-Surgical Confusion, and Dementia in the Elderly: An Unexpected Connection but with the Same Proposed Solution.
Topics: Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Confusi | 2018 |
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.
Topics: Animals; Docosahexaenoic Acids; Immunity, Cellular; Ketorolac; Male; Mice; Mice, Knockout; Neoplasm | 2019 |
The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population.
Topics: Aged; Anesthesia, Conduction; Anesthesia, Epidural; Anesthesia, General; Anti-Inflammatory Agents, N | 2013 |
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Analysis of Variance; Anti-Inflammatory Agents, Non-Ste | 2010 |
NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Combined Mod | 2012 |